Lamond David 4

What Happened

• Director David Lamond was granted a derivative equity award covering 2,700 shares of Quince Therapeutics on 2026-06-11. The award is reported with an acquisition price of $0.00, so there is no immediate cash outlay or recorded purchase value.
• This grant is a stock option-style award (derivative) and will vest 100% on the one-year anniversary of the grant date, per the filing footnote. Because this is a compensation grant rather than an open-market purchase or sale, it is typically administrative/compensation-related rather than a clear bullish or bearish trading signal.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (timely filing).
• Security: derivative award covering 2,700 shares; reported acquisition price: $0.00.
• Vesting: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date (footnote).
• Shares owned after the transaction: not specified in the provided filing details.
• Filing timeliness: filed within required reporting window (not indicated as late).

Context

• This was an equity award (derivative) granted as part of compensation. Such grants do not require an immediate cash payment and often vest over time; here the entire grant vests after one year.
• Awards and option grants are routine for directors and executives; they signal alignment with shareholders but are not direct purchases of stock on the open market.